Datroway, a specifically engineered TROP2-directed antibody drug conjugate or ADC, was discovered by Daiichi Sankyo, and is being jointly developed and commercialised by AstraZeneca and Daiichi ...

Datroway is a targeted trophoblast cell surface antigen 2 (TROP2)-directed DXd antibody drug conjugate (ADC), developed using Daiichi Sankyo's DXd ADC Technology.

First approval in the EU for Daiichi Sankyo and AstraZeneca’s DATROWAY based on TROPION-Breast01 trial showing 37% reduction in the risk of disease progression or death versus chemotherapy ...

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialize fam-trastuzumab deruxtecan-nxki in March 2019 and DATROWAY in July 2020, except in Japan ...

Datroway is a specifically engineered TROP2-directed DXd antibody drug conjugate or ADC discovered by Daiichi Sankyo, and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

Daiichi Sankyo and AstraZeneca are evaluating DATROWAY plus rilvegostomig as first-line treatment for patients with advanced or metastatic nonsquamous NSCLC with PD-L1 ≥50% and without ...

AstraZeneca and Daiichi Sankyo's Datroway secured a lung cancer approval from the FDA. And more. 1. Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions ...

Daiichi Sankyo recognizes Datroway’s sales in the U.S. This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR).